Abstract:Hodgkin lymphoma (HL) is a highly curable disease with 5-year survival greater than 95%. 1 However, these survival rates are achieved at great cost with regard to long-term cardiovascular morbidity, given the historic reliance on mediastinal radiation and anthracycline chemotherapy. In the Childhood Cancer Survivor Study (CCSS), which includes survivors of pediatric cancer diagnosed between 1970 and 1999, the risk of major cardiac events by age 45 years was greater than 10% in patients who received both anthracyclines and chest radiation. 2 In an effort to reduce this risk, important treatment modifications have been made over time, including the introduction of dexrazoxane cardioprotection, reduction in the use of radiotherapy, and, when radiation is used, delivery of lower mean cardiac radiation doses. However, currently available data regarding long-term cardiovascular outcomes after HL therapy do not reflect these more recent changes to treatment regimens. Precise estimates of cardiovascular risks are critical to assess the potential risks and benefits of existing and emerging treatment regimens and to determine optimal patient surveillance strategies during survivorship. In this issue of JAMA Network Open , Lo et al 3 present a cohort study of 2563 intermediate- and high-risk patients with pediatric Hodgkin lymphoma enrolled across 4 Children's Oncology Group (COG) clinical trials (AHOD0031, AHOD0831, AHOD1331, and S1826) spanning from 2002 to 2022. The investigators acquired mean heart dose from cardiac contours in radiation therapy plans, and treatment exposures were obtained from COG trial databases. Using risk estimates from prior CCSS analyses and studies of dexrazoxane's cardioprotective effects, Fine and Gray models were used to estimate the hazard of grade 3 to 5 cardiac disease associated with demographic and treatment characteristics and the cumulative incidence of cardiac diseases in the average patient aged 15 years in each trial. From the earliest of these COG trials to the most recent, the use of mediastinal radiotherapy decreased significantly (from 40% in AHOD0031 to 1% in S1826) as did the median mean heart radiation dose (from 15.0 Gy to 3.8 Gy). Additionally, the cumulative anthracycline dose increased in the most recent trials (from 200 mg/m 2 to 300 mg/m 2 ), while the use of dexrazoxane cardioprotection increased from 0% to 80%. The combined effect of these changes reduced the estimated 30-year cumulative incidence of cardiac disease from 9.6% in AHOD0031, the earliest trial, to 6.2% for the average patient aged 15 years who was treated in the most recent trial, S1826. Additional refinements to limit cardiotoxic effects, including reduction of cumulative anthracycline dosage to 200 mg/m 2 and 100% dexrazoxane use, would result in a relatively small further estimated reduction in the cumulative incidence of cardiac disease. This study by Lo et al 3 provides important insight into the consecutive improvements in cardiovascular morbidity achieved through Hodgkin therapy modifications over the past 2 decades. Although a 3.4% reduction in the 30-year cumulative incidence of serious cardiac events represents meaningful progress in reducing the late effects of HL therapy, it is important to assess the residual burden of cardiovascular events in the context of background risk. Previous CCSS analyses have estimated a cumulative incidence of serious cardiovascular events approaching 2% to 4% in comparable cancer survivors aged 45 years and treated without anthracycline or cardiac radiation and approximately 1% to 2% in sibling controls. 2 Thus, a residual 6.2% 30-year incidence of serious cardiovascular events leaves further opportunity for improvement. As emerging regimens rely more heavily on CD30-targeting and immunotherapies, the role of chemotherapy and radiation may become less critical. Specific estimates of the cardiovascular benefit of therapy modifications, such as those provided through this analysis, will inform future trials aiming to balance the reduction in late effects with potentially higher relapse risk as chemotherapy and radiation therapy are reduced. Furthermore, although relapsed HL is generally salvageable, the cardiotoxic effects of salvage therapies must also be considered. Reliance on auto hematopoietic cell transplant (auto-HCT) consolidation for relapsed HL has led to a substantial burden of cardiac and late effects, similar to that seen after high-dose, extended-field radiation used in the 1970s. 4 Current research seeks to identify transplant-free salvage regimens for select patients to reduce transplant-associated late effects (ClinicalTrials.gov ID: NCT02927769, NCT03618550). However, these salvage regimens may also contribute to cardiotoxic effects. For example, lesion-based radiotherapy is an alternative to consoli -Abstract Truncated-

Posterior reversible encephalopathy syndrome (PRES) in classic Hodgkin's lymphoma, complicated by anthracycline-induced cardiomyopathy

Chemotherapy-associated hemorrhagic posterior reversible encephalopathy syndrome (PRES) with considerations for circle of Willis variants on cerebral blood flow and autoregulation: A case report

A Rare Case of Cyclophosphamide-Induced Posterior Reversible Encephalopathy Syndrome in a Patient With Acute Lupus Nephritis Flare

Variant Type of Posterior Reversible Encephalopathy Syndrome with Diffuse Cerebral White Matter and Brainstem Involvement Associated with Intracranial Hemorrhage.

Primary brain tumors and posterior reversible encephalopathy syndrome

Management and Clinical Outcome of Posterior Reversible Encephalopathy Syndrome in Pediatric Oncologic/Hematologic Diseases: A PRES Subgroup Analysis With a Large Sample Size

CARDIOTOXICITY RISK IN PATIENTS WITH NON‐HODGKIN LYMPHOMA RECEIVING EPOCH AFTER PRIOR ANTHRACYCLINE EXPOSURE

Rituximab as a possible cause of posterior reversible encephalopathy syndrome

Approach to Lymphoma-Associated Cardiomyopathy

Toxic Cardiomyopathy in a Young Patient Treated for Her2-Positive Early Breast Cancer: Case Report and Literature Review

Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management

Posterior Reversible Encephalopathy Syndrome (PRES) after Haploidentical Haematopoietic Stem Cell Transplantation: Incidence, Risk Factors and Outcomes

Acute cardiomyopathy following a single dose of doxorubicin in a patient with adult T-Cell leukemia/lymphoma

Secondary lymphoma develops in the setting of heart failure when treating breast cancer: A case report

Assessment of Chemotherapy-Induced Cardiac Dysfunction in Breast Cancer Patients: A Prospective Study

Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors

Cardiac Risk Reduction With the Evolution of Pediatric Hodgkin Lymphoma Therapy

A case report on posterior reversible encephalopathy syndrome (PRES) in an elderly female

Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.

Low incidence of cardiotoxicity in patients with non‐Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure